J.Molner
Press release from First North

J. Molner submits drug application to U.S Food and Drug Administration (FDA)

Tallinn, 2023-07-13 08:00 CEST -- J. Molner has successfully presented its first complete submission to the U.S Food and Drug Administration. Molner’s generic topical drug, MOL-004, is subject to FDA review and may be eligible for approval in the first half of 2024.

         For additional information please contact:
         Jason Grenfell-Gardner
         J. Molner AS
         Management Board member
         +372 536 00 346
         jason@jmolner.com